{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031996","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.842973+00:00","generated_at":"2026-06-08T04:18:52.038119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Perspective Therapeutics Q3 revenue up 27% to $2.19M; net loss widens to $10.4M","bullets":["Revenue $2.19M (+27% YoY); sales revenue $1.9M (+11%); gross profit $738K vs $414K.","Net loss $10.4M ($0.04/sh) vs $4.1M ($0.03/sh); R&D expenses surged 708% to $5.7M.","Cash $18.0M at Sept 30, 2023 (from $43.9M at Dec 31, 2022); runway into late Q2 2024.","Dosed first patient in Phase 1/2a trial of [212Pb]VMT-α-NET for neuroendocrine tumors.","Completed recruitment for first cohort of Phase 1/2a VMT01 trial for melanoma; no serious AEs."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031996","json":"https://secwatch.observer/filing/0001437749-23-031996.json","markdown":"https://secwatch.observer/filing/0001437749-23-031996.md","text":"https://secwatch.observer/filing/0001437749-23-031996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/0001437749-23-031996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/isr20231113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:18:52.038119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40b292e4dca2a9326d0d0efa1cfd72eed55babe6","claim":"Perspective Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"issued a press release announcing its financial results for the quarter ended September 30, 2023 and providing recent business highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923031996/0001437749-23-031996-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}